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Abstract
Purpose of review—The goal of this paper is to review recent research on the identification and 
treatment of prodromal periods that precede bipolar and psychotic disorders. We also sought to 
provide information about current best clinical practices for prodromal youth.
Recent findings—Research in the areas of identifying prodromal periods has rapidly advanced. 
Calculators that can predict risk are now available for use during both bipolar and psychotic 
disorder prodromes. Cognitive behavior therapies have emerged as the gold standard psychosocial 
interventions for the psychosis prodrome, while several other types of therapies hold promise for 
treatment during the bipolar prodrome. Due to safety and efficacy concerns, pharmacologic 
treatments are not currently recommended during either prodromal period.
Summary—While additional research is needed to develop useful clinical tools to screen and 
diagnose during prodromal phases, existing literature has identified constellations of symptoms 
that can be reliably identified in research settings. Specialized psychotherapies are currently 
recommended to treat prodromal symptoms in clinical settings. They may also be useful to curtail 
future episodes, although further research is needed.
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Introduction
Diagnoses of schizophrenia and bipolar disorder are both preceded by a prodromal period, 
typically lasting months or years, in which sub-syndromal symptoms begin to manifest [1, 
2]. This review discusses the current state of research in the prodromes of both 
schizophrenia and bipolar disorder. We focus on symptomotology and its ability to predict 
conversion to schizophrenia and bipolar disorder, identification of the prodrome in the clinic 
and possible interventions.
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Part I: Schizophrenia prodrome
Introduction to the prodromal period
The prodromal phase of schizophrenia represents a period of functional change which 
proceeds the onset of the first-episode of psychosis. It represents a deviation from a person’s 
previous experience and behavior, occurring from the emergence of the first noticeable 
symptoms to the appearance of the first prominent psychotic symptoms. The term 
“prodromal” was introduced first by Mayer-Gross in 1932 [3], though the earliest studies of 
the phenomenon occurred in the late 1980s and early 1990s when work by researchers such 
as Häfner and colleagues demonstrated that schizophrenia was proceeded by the prodromal 
phase in up to 73% of all patients [4–7]. The prodromal phase is thought to last on average 
between one and five years [8] and is itself associated with not inconsequential amounts of 
psychosocial impairment and disability [9]. The literature often refers to individuals in the 
prodromal phase as at “clinical high risk” (CRH), “ultra high risk” (UHR), or having “at risk 
mental states” (ARMS) [10]. We will use the phrase “prodromal phase” to refer to 
individuals experiencing this phase.
The prodromal phase is a heterogeneous phenomenon. It is associated with depression, 
disrupted concentration and sleep, avolition, social isolation and even mild attenuated 
psychotic experiences [10–14]. Attenuated psychotic symptoms are of particular importance, 
as these experiences are thought to represent the later phase of the prodrome, and thus are a 
harbinger of transition to the onset of the first-psychotic episode [10]. Examples of 
attenuated psychotic symptoms include referential thinking, magical thinking, or difficulties 
with reality testing. Other individuals may begin experiencing poorly formed hallucinatory 
experiences, such as mumbled voices or brief visual hallucinations. Some individuals may 
act erratically, while others become anxious or withdrawn [10]. Many in the prodromal 
phase of schizophrenia may experience neurocognitive deficits. Meta-analyses have 
demonstrated diffuse, mild cognitive impairments in the prodrome, with functioning falling 
in between that of healthy individuals and those with schizophrenia [15, 16]. Importantly, 
the cognitive deficits may not only predict who is at greater risk to convert but also predict 
poorer psychosocial functioning [1].
Identifying the prodromal period
Over the last twenty years there has been increased focus on identifying individuals in the 
prodromal phase of psychosis. This can be a challenge for busy clinicians, however, 
considering the heterogeneity of prodromal phase presentation. Prodromal individuals who 
present to psychiatrists are typically help-seeking, but generally come to attention for co-
occurring diagnoses rather than concern for psychosis. Frequently observed comorbid 
conditions include depression, anxiety, or substance use [17, 18]. Additionally, the 
prodromal phase of psychosis is often associated with suicidal ideation. A study by Hutton 
and colleagues examined the prevalence of suicidality in prodromal individuals, observing 
that 59% reported suicidal ideation. Furthermore, at least 47% of individuals in this cohort 
acknowledged having at least one suicide attempt before ultimately entering into treatment 
[19].
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In spite of the difficulty in identifying those in the prodromal phase of psychosis, researchers 
have continued to make strides in refining the approach to the screening and treatment of 
these individuals. Estimating the prevalence of prodromal phase psychosis in the general 
population is difficult, as most estimates are based on patients who are presenting for 
treatment and may not reflect the potentially large number of individuals who do not seek 
help. Furthermore, treatment decisions may be complicated by the fact that of those 
individuals 12–35 years of age who present with signs of prodromal psychosis, only 
approximately 20–35% will actually go on to experience a first psychotic episode over a 
two-year period [20]. Current structured psychometric interviews, including the 
Comprehensive Assessment of the At-Risk Mental State (CAARMS) [21], the Structured 
interview for Psychosis-Risk Syndrome (SIPS) [22], the Basel Screening instrument for 
Psychosis (BSIP) [23], and the Bonn Scale for the Assessment of Basic Symptoms [24], 
have been observed to be consistently valid in identifying those with prodromal psychosis 
[20]. However, individuals identified by these instruments have only a 30–35% risk of 
transition to a psychotic illness over three or more years [25]. Thus, it is imperative that 
additional factors be incorporated into predictive models, enabling more accurate prediction 
of who will develop a psychotic illness. Furthermore, it is important to develop tools which 
are generalizable to a broader population, rather than primarily treatment seeking 
individuals. This type of work was recently published by Cannon et al., reporting exciting 
data from the second phase of the North American Prodrome Longitudinal Study (NAPS-2). 
This study combined not only demographic (e.g., age, family history of psychosis) and 
clinical data (e.g., unusual thought content, suspiciousness) but also neurocognitive (e.g., 
verbal learning and memory, speed of processing) and psychosocial data (e.g., traumas, 
stressful life events, and decline in social functioning) to generate an individualized risk 
calculator for psychosis which could theoretically be applied at initial clinical contact. This 
calculator was found to be effective at predicting conversion to psychosis at a level 
consistent with other predictive calculators used for cardiovascular disease and cancer 
recurrence risk [26]. Furthermore, since this calculator is designed to examine risk of people 
at the individual level it inherently accommodates the heterogeneity of individuals in the 
prodromal phase of psychosis. However, the authors point out that this tool is likely to be 
most effective in clinical trial situations. Notably, this risk calculator begins in a position 
assuming that an individual has screened positive for a prodromal risk syndrome. If the 
individual has yet to do so, the risk calculator is unusable. Importantly the authors also note 
that risk determinations and the ramifications of these results can be potentially confusing or 
distressing to patients and families, and thus these data should be explained by trained 
clinicians who can help patients and families understand these results [26].
An issue for clinicians who are interested in the identification of prodromal phase 
individuals is the length and training necessary to complete these screening measures. A 
review by Addington (2015) sought to examine the suitability of existing screening tools 
which are brief and practical instruments for initial evaluation of subjects in busy clinical 
settings where an in-depth assessment may not be feasible. The authors posit that to be 
effective and useful, a screening instrument would need to balance brevity and ease of 
administration with the ability to reliably distinguish those who are or are not at high risk for 
psychosis. 17 screening instruments were considered, with the data revealing significant 
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variations in key factors such as sensitivity (67–100%), specificity (39–100%), and positive 
and negative predictive value (24–100% and 58–100%, respectively). The authors ultimately 
concluded that brief screening measures are generally underexplored and require more high-
quality evaluations before they can be recommended [27]. This is not to say there is no 
future utility in the use of these measures, but rather to call for further research into 
clinically useful screening devices and validation of existing scales.
Treatment
A clinical question remains after the identification of prodromal phase patients using even 
the most accurate of predictive tools: What is the role of treatment for the prevention of the 
first episode of psychosis? Proponents of treating individuals in the prodromal phase of 
psychosis cite not only a need to prevent or mitigate the impact of a first psychotic episode, 
but also the substantial amount of distress that can be seen within the prodrome itself [17]. 
Individuals in the prodromal phase often experience depression, anxiety, memory and 
attention deficits, and significant social isolation [10]. The literature demonstrates that these 
phenomena are associated with impaired functioning and decreased quality of life [28, 29]. 
The benefits of preventing the onset of psychosis seem obvious. Not only is the first episode 
of psychosis associated with significant disruptions in an individual’s life, but for many this 
marks the onset of a life-long, potentially severe mental illness. Meta-analyses examining 
the effectiveness of prodromal phase interventions demonstrate a pooled effect indicating 
that treatment is successful for preventing psychosis conversion [10, 30–32]. Specifically, 
mean relative reductions of 64% at 6 months, 54–56% at one year, and 35–42% at 2–4 years 
has been demonstrated. It must be noted, however, that in spite of support for focused 
interventions for those in the prodromal phase, there are varying levels of support for the 
different treatment options [1, 10].
The best studied prodromal phase intervention is cognitive behavioral therapy (CBT). Early 
research demonstrated that CBT was associated with decreased symptoms, better 
functioning, and decreased rate of transition to psychosis [33–37]. These studies have 
focused on strengthening thought and behavior monitoring, schema testing, and coping 
skills. Newer research continues to support CBT in prodromal individuals. A study by Insing 
and colleagues demonstrated that CBT for prodromal phase was effective at mitigating 
conversion risk in the short-term and that this effect was maintained at follow-up four years 
later. Additionally, this studied provided evidence that CBT was associated with increased 
likelihood of prodromal phase remission [38]. A limitation of CBT studies is that there is 
heterogeneity in the CBT protocols. However, as CBT has proven successful for the 
treatment of symptoms associated with prodromal phase psychosis, such as depression or 
anxiety, much of the current literature recommends CBT as an early and safe intervention. 
Therefore, CBT should be offered before riskier interventions such as antipsychotic 
medications [10, 37].
Other therapeutic options that have been examined for the treatment of prodromal phase, 
include family therapy, cognitive remediation, supportive therapy, social skills training, and 
supported employment or education. The effectiveness of these strategies varies across trials, 
but generally speaking all are benign and, as such, are recommended for use prior to 
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antipsychotic initiation. Some investigators have attempted to offer integrated treatment 
models, such as the Early Psychosis Prevention and Intervention Centre (EPPIC) [39], 
OPUS [40] and Family-aided Assertive Community Treatment (FACT) [41]. These 
programs offer an array of psychotherapeutic, educational, and if indicated, medication 
treatment options. Important questions remain about the effectiveness of integrated treatment 
programs, including which services are more or less effective.
A controversial aspect of the treatment of the prodromal phase of psychosis is the use of 
antipsychotic medications. Though these medications may be used to treat attenuated 
symptoms of psychosis, they are by no means benign and it is unclear what role they may 
have in actually preventing a transition to psychosis. Antipsychotic medications are 
associated with side effects including weight gain, sedation, sexual dysfunction, and, in the 
long-term, extra-pyramidal symptoms [42–44]. Furthermore, it has been shown that younger 
individuals may be more sensitive to the metabolic effects associated with second generation 
antipsychotics [45], raising the question of whether or not to use these agents in the 
prodromal phase. There are only a handful of studies that have examined the impact of 
antipsychotic medication on psychosis conversion. McGorry and colleagues conducted 
separate studies examining the impact of risperidone plus other interventions, such as CBT 
and needs based intervention versus therapeutic intervention alone, finding that both groups 
improved functionally and symptomatically but that the effects of the risperidone were 
difficult to interpret [39, 46]. A trial by McGlashan et al. examined a trial of olanzapine 
versus placebo for prodromal phase treatment. In this study olanzapine was associated with 
greater symptom improvement than placebo, though both groups were associated with 
significant functional improvement. Additionally, the olanzapine group was associated with 
significantly more sedation and weight gain [47]. More recently in a multi-site study, Woods 
and colleagues examined the safety and efficacy of ziprasidone for preventing or delaying 
the onset of psychosis in 51 prodromal phase subjects. Subjects received 24 weeks of 
ziprasidone or placebo as well as a supportive therapy session at each research visit. The 
study was limited by the small sample size, which yielded only two converters in the placebo 
group and one in the active group. As such, the authors were not able to demonstrate an 
effect of ziprasidone on psychosis conversion risk. They did demonstrate an effect on 
attenuated symptoms of psychosis and a paucity of weight gain or ECG effects among 
subjects with psychosis (most of whom did not experience frank psychotic episodes)[48]. 
This points towards a potential role for metabolically neutral antipsychotic medications for 
use in those in the prodromal phase, though certainly much more research is needed in this 
area. At the current time the consensus on antipsychotic medications is that they are 
effective in treating attenuated psychotic symptoms, but should be used only when initial 
treatments have failed to work or when an individual begins demonstrating rapidly 
progressing or debilitating signs of psychosis, portending a potential psychotic break [30, 
37, 49].
Not all medication studies have focused on antipsychotic use, as there have been 
investigations of more benign agents for conversion prevention, with the majority of work 
examining the role of omega-3-fatty acids. In 2010 Amminger and colleagues randomized 
81 subjects to a 12-week intervention of omega-3-fatty acids (1.2 grams per day) versus 
placebo. They then monitored subjects for a period of 40 weeks following study termination, 
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examining the rate of psychosis transition as well as symptomatic and functional changes. In 
comparison to the study by Woods and colleagues, which was limited by the low number of 
converters, the Amminger study did reveal a significant effect of treatment, demonstrating a 
difference in cumulative risk of progression to psychosis of 22.6%. This study also 
demonstrated positive effects on overall symptomatology [50]. In spite of the promising 
initial data, subsequent studies have been less successful. A study by Nelson et al. attempted 
to replicate the findings by Amminger et al in a large, multi-center trial. This study 
randomized 304 subjects with psychosis prodrome from 10 different specialized early 
psychosis treatment centers. Subjects received either 1.4 grams of omega-3-FA plus up to 20 
sessions of cognitive-behavioral case management (CBCM) or placebo plus CBCM. 
Subjects received six months of treatment and were then monitored for transition as well as 
symptom and functional status. The results of this trial did not replicate the initial Amminger 
findings, as there was no difference in transition rates between the two groups at either six or 
twelve-months. The authors posited that this may have been due to the lower than expected 
transition rate between the two groups (11% of the whole sample). Additionally, in this 
study both groups demonstrated significant overall symptom and functional improvement, 
which may have confounded results [51].
Conclusions on the schizophrenia prodrome
The literature on prodromal phase presentation, screening, and intervention clearly calls for 
continued research in this area. Prodromal phase screening is important, as these individuals 
experience distressing symptoms such as depression, anxiety, impaired concentration, and 
social impairments. These experiences result in disruptions in overall functioning, even in 
those who do not develop a subsequent psychotic illness. Existing methods to screen and 
diagnose individuals with psychosis prodrome have been thoroughly examined here. These 
tools require trained raters and are time consuming to administer, decreasing their yield in 
busy clinical settings. Some research has focused on brief tools for prodromal phase 
screening, though more work is needed in order to develop a tool that will be practical for 
use outside of research settings. Additionally, much more work examining prodromal phase 
interventions is needed. The literature is clear on the need for early intervention to prevent 
the transition to psychosis or to mitigate the symptoms and functional impairments 
associated with psychosis [1, 10, 52, 53]. The most effective means of doing so, however, 
have yet to be elucidated. At this point, a number of research groups have published expert 
consensus guidelines on psychosis prodrome intervention, highlighting a focus on early 
identification efforts, avoiding drugs of abuse, treating comorbid psychiatric symptoms such 
as depression and anxiety, and withholding antipsychotic medications until severe functional 
changes or psychotic symptoms occur. However, more work utilizing metabolically neutral 
agents, such as the Addington study with ziprasidone, would help further refine our 
understanding of the role of antipsychotic medication use and side effect profile.
For busy clinicians, a number of takeaway points may be gleaned from the literature. The 
first and perhaps most important point is to not ignore early signs of the prodromal phase. 
Though the field is still refining identification and predictive measures, prompt referral to 
experts may result in early intervention and improved long-term functioning and outcomes. 
Second, even if psychosis prodrome is suspected, prompt treatment of comorbid issues such 
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as depression, anxiety, or substance abuse should be initiated. However, one should be 
mindful to avoid medications with a risk of contributing to psychotic phenomenon, such as 
stimulant medications. Finally, clinicians should be thorough and deliberate in discussing the 
prodromal phase and providing education for families and patients. Alongside providing 
appropriate referral information, clinicians should provide clear guidance on risk and 
protective factors which are not only generally applicable but also relevant to each individual 
patient and family.
Part II: Bipolar Prodrome
Introduction: What is the bipolar disorder prodrome?
The bipolar disorder prodrome, although less studied than the psychosis prodrome, has 
received increasing attention in recent years. Typical age of onset for bipolar disorder is 
adolescence to young adulthood. The bipolar disorder prodrome comprises precursor 
symptoms, functional impairments, and other psychiatric diagnoses present in the months or 
years prior to bipolar disorder onset. Recent reviews of prospective studies have provided 
information about bipolar disorder precursors (affective symptoms prior to bipolar disorder 
diagnosis) [2] and clinical risk factors (non-affective psychopathology prior to bipolar 
disorder diagnosis) [54]. In a combination of hospitalized and community samples, 
precursors included, anxiety disorders, mood lability and mood swings, cyclothymia, 
subthreshold manic and hypomanic symptoms, subsyndromal depression, psychotic features 
in the context of depression, and early age of onset of depressive episodes [2]. In community 
and outpatient samples, clinical risk factors included early onset panic attacks, separation 
anxiety disorder, generalized anxiety disorder, conduct symptoms and disorder, ADHD, and 
impulsivity, with anxiety disorders being the most reliable risk factors [54].
Studies of bipolar disorder offspring are beginning to provide information about which 
prodromal symptoms are most predictive of development of bipolar disorder. Children of 
parents with bipolar disorder are at increased risk of multiple psychiatric disorders, 
including depressive and anxiety disorders, ADHD, oppositional defiant disorder, disruptive 
mood regulation disorder, and substance use disorders, as well as chronic irritability [55–
57]. In several cohorts, 8–10% of offspring had developed a hypomanic, manic, or mixed 
episode, or frank bipolar disorder, by their mid to late teens [55, 56]. Subthreshold manic 
and hypomanic symptoms appear to be the best predictors of eventual, and imminent, 
bipolar disorder diagnosis in a cohort of over 300 high-risk offspring [55, 58]. Chronic 
irritability was associated with higher likelihood of bipolar disorder diagnosis [57]. Parent 
reports of both externalizing and internalizing symptoms, and child reports of mood lability, 
were predictive of conversion to bipolar disorder diagnosis [58]. Of note, the majority of 
high-risk offspring who went on to have a manic or hypomanic episode had a previous 
depressive episode and a non-mood psychiatric diagnosis (ADHD, anxiety disorder, etc.) 
[55].
The timing and course of the bipolar disorder prodrome is variable. Several studies have 
noted the prodrome onset and progression to frank bipolar disorder as gradual, rather than 
rapid [59, 60]. Most often, symptoms are present for several years before bipolar disorder 
develops, with a retrospective meta-analysis finding a mean duration of just over two years 
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[61]. Of note, chronic, non-episodic irritability in children, once thought to be associated 
with later development of bipolar disorder, is actually associated with later unipolar 
depression and/or anxiety disorders [62].
It is clear that the bipolar disorder prodrome does have some symptomatic overlap with the 
PP, and they can be difficult to distinguish clinically. One study found that obsessions and 
compulsions, suicidality, difficulty thinking, depressed mood, difficulty concentrating, poor 
energy, and mood lability were more likely to develop into mania/bipolar disorder, while 
subsyndromal unusual ideas were more associated with development of psychosis [60].
Tools for clinical identification of the bipolar disorder prodrome
No biomarkers have yet been validated for the bipolar disorder prodrome [63]. Several tools 
attempting to predict bipolar disorder have been developed, mostly based on the bipolar 
disorder prodrome symptoms discussed above. The Bipolar Disorder At-Risk (BAR) criteria 
are a set of clinical and familial characteristics thought to be highly predictive of transition 
from unipolar depression to bipolar disorder. They include sub-threshold mania, depression 
with cyclothymic features, and depression with family history of bipolar disorder [64]. 
These have been extended to include other risk factors, including antidepressant-emergent 
elation and atypical depression. Number needed to screen (NNS) in a routine clinical setting 
(taking into account what may or may not be recorded in a typical clinic note) has been 
estimated to range from 3.5 to cyclothymia to 6.9 for subthreshold mania [65]. Another tool, 
the Bipolar Prodrome Symptom Interview and Scale-Prospective (BPSS-P), takes 1.5 to 2.5 
hours in psychiatric patients and their caregivers. So far, it has been found to be 
psychometrically sound but no predictive validity has yet been established [66].
A tool has been developed specifically for high-risk youth (i.e., offspring of bipolar disorder 
patients aged 8–17), enabling calculation of a personalized risk of developing bipolar 
disorder in the next 5 years [67]. It is available at http://cabsresearch.pitt.edu/calculator/
BPRiskCalculator.html. Clinician administration of five different psychometric scales 
(measuring depression, mania, affective lability, anxiety, and global function), plus parent’s 
age of onset, are required for the calculation.
Treatments
Both psychosocial and pharmacologic treatments have been studied in the bipolar disorder 
prodrome [68], as in the PP, although the amount of available evidence so far is less in the 
bipolar disorder prodrome. Most of these studies have been conducted in patients at high 
risk for bipolar disorder, usually based on family history. Clearly, the risk-benefit ratio based 
on current evidence favors psychosocial over pharmacologic treatment.
Psychosocial treatments—Psychosocial interventions for individuals at high risk for 
bipolar disorder have been reviewed recently [69]. Most of these studies involve at-risk 
youth and their families. Some studies provide evidence of symptom reduction, or even 
decreased likelihood of conversion to bipolar disorder. There are very few published RCTs 
in this area.
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Multifamily psychoeducational psychotherapy for 8 weeks has been studied in an RCT of 9–
11 year olds with depressive spectrum disorders. Transient manic symptoms were present 
(n=37) or absent (n=13). Over the following 18 months, 48% of patients with transient 
manic symptoms converted to bipolar disorder, while 12.5% of patient with only depressive 
symptoms converted to bipolar disorder. Treatment, compared to waitlist control, was 
associated with a four-fold decrease in risk for conversion (12% vs. 45%). Family history, 
manic symptoms, and lower overall baseline function were associated with conversion to 
bipolar disorder [70].
Family-focused treatment (FFT) has been tested in 9–17 year olds with mood symptoms but 
no bipolar disorder diagnosis, and a family history of bipolar disorder [71]. An RCT of FFT 
in 12 manualized sessions with patient and family showed more rapid recovery, more time in 
remission, and better trajectory of manic symptoms over a 1-year period in 40 patients 
compared to a 1–2 session psychoeducation control [72]. A multisite trial of FFT is 
underway currently [73].
A pilot study of Interpersonal and Social Rhythm Therapy examined high-risk 13–28 year 
olds with a family history of bipolar disorder and with or without personal history of 
psychopathology (except bipolar disorder). Of 19 participants, 13 attended at least one 
session of treatment. Over six months, these 13 patients attended about 50% of sessions and 
showed significant changes in sleep and circadian patterns (which are specifically targeted 
by the intervention). No changes in mood were detected [74].
A small study evaluated the effects of both individual family psychoeducational 
psychotherapy and omega-3 supplementation. A total of 23 patients with subsyndromal 
bipolar disorder symptoms (cyclothymia or bipolar disorder-NOS) were randomized to the 
12-week psychotherapy intervention or active monitoring and to omega-3 supplementation 
or placebo (4 groups, n=5–7 each). Neither treatment significantly reduced manic symptoms 
compared to control; all four groups showed decreases in manic symptoms during the study. 
The psychoeducational psychotherapy intervention had a medium to large effect size on 
depressive symptoms and the omega-3 supplementation had a medium effect size on 
depressive symptoms. Both treatments were well-tolerated [75].
Pharmacotherapy—To our knowledge, only five studies have examined 
pharmacotherapies in patients at high risk for bipolar disorder. All were in children and/or 
adolescents with parental or strong family history of bipolar disorder, with some degree of 
psychopathology but no diagnosis of bipolar disorder I (also reviewed in [76, 77]). Of note, 
none of these studies had prevention of development of bipolar disorder as an endpoint.
The first trial of mood stabilizing medication in this population was a double blind RCT of 
lithium (n=17) vs. placebo (n=13) in children (average age 11) with MDD and no history of 
(hypo)mania, at high familial risk of developing bipolar disorder [78]. After six weeks at a 
therapeutic lithium level, no group differences were found on the Kiddie Schedule for 
Affective Disorders and Schizophrenia (KSADS). Dose-limiting side effects were 
problematic in this study: three of the participants in the lithium group were discontinued 
from treatment due to confusion/forgetfulness, and one due to nausea and vomiting.
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Three studies have examined divalproex in children at high risk for bipolar disorder. In the 
first study [79], 24 children (average age 10) received 12 weeks of open-label divalproex. 
All had DSM-IV diagnoses of MDD, dysthymia, cyclothymia, or ADHD. Eighteen of 23 
patients who completed the study (78%) were “much improved” or “very much improved” 
on the Clinical Global Impression-Improvement scale. No patients dropped out due to side 
effects; one patient dropped out after 2 weeks of treatment due to ongoing symptoms. In a 
second study of divalproex [80], high-risk children diagnosed with bipolar NOS or 
cyclothymia were enrolled in an RCT comparing divalproex (n=29) to placebo (n=27). 
Average age was 10, and patients could remain in the study up to five years. The main 
outcomes were time to discontinuation for any reason and time to discontinuation due to a 
mood event. Neither outcome differed between groups. No group differences in mania or 
depression symptoms, or in overall function, were found, although both groups improved 
over time in both symptoms and function. Divalproex was well tolerated and no patients 
dropped out due to side effects. In a third, pilot study of divalproex, high-risk children in an 
MDD episode were treated with paroxetine (n=4) or paroxetine plus divalproex (n=5) in a 
randomized, open-label fashion [81]. Average age was 12. The study was discontinued after 
enrolling 9 patients as over half of these patients developed either manic symptoms or 
suicidality after a mean treatment time of 22 weeks. Prominent sedation was noted among 
the patients in the combination therapy group.
Only one study of antipsychotics in a high-risk for bipolar disorder population exists. 
Twenty high-risk adolescents (mean age 14.7) were enrolled in a single-blind study of 
quetiapine for 12 weeks [82]. All had diagnoses of bipolar NOS, bipolar II, cyclothymia, or 
MDD. 15 patients completed the study (2 were lost due to nonadherence, 2 due to lack of 
efficacy, and 1 due to withdrawal of consent/assent). Thirteen of fifteen patients completing 
the study responded to quetiapine (defined as “much improved” or “very much improved” 
on the CGI-I). Both manic and depressive symptoms also showed statistically significant 
improvement. Quetiapine was well tolerated and no patients dropped out due to side effects. 
Patients gained an average of 0.4 kg over the study period.
A pilot study of omega-3 fatty acids combined with family psychoeducational 
psychotherapy (see above) found preliminary evidence of omega-3’s effect on depressive 
symptoms in patients with subsyndromal bipolar disorder. The supplement was well-
tolerated [75].
A pharmacologic algorithm for guiding clinical care has been studied in 40 youth at high 
risk for bipolar disorder with depressive, manic, anxious, or ADHD symptoms for 1 year 
[77], but psychiatric outcomes, including development of bipolar disorder, have not yet been 
established. Of note, no treatment-emergent mania was detected in this study, despite the 
facts that 1) ADHD symptoms were treated with stimulants in some cases, and 2) 
antidepressants were used in patients with unipolar depression and no history of 
antidepressant-induced mania.
In sum, the existing literature on pharmacotherapy for prevention in individuals at high risk 
for bipolar disorder currently provides overall little evidence of benefit, and no study has 
demonstrated prevention or delay of ultimate development of bipolar disorder. Additionally, 
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particularly in pediatric populations, longer-term effects of mood stabilizing medications 
must be considered: valproate, for example, has been tied to development of polycystic 
ovarian syndrome and other reproductive endocrine disorders [83]. Antipsychotics (as 
discussed in the psychosis prodrome section above) are associated with metabolic effects 
including weight gain and type 2 diabetes.
Bipolar prodrome conclusions and clinical considerations
Overall, despite being a younger field than the PP, the study of the bipolar disorder 
prodrome has led to the identification of precursors and risk factors for bipolar disorder. The 
bipolar disorder prodrome is characterized primarily by anxiety disorders. Clinical tools for 
identifying the BPD are in early stages of development. Psychosocial interventions have 
shown promise in improving symptoms of the bipolar disorder prodrome and perhaps even 
delaying bipolar disorder onset, although more studies are needed. Mood stabilization with 
medications in the bipolar disorder prodrome has so far shown little utility and side effects 
are an important concern.
For clinicians, patients suspected of being in the bipolar disorder prodrome should be 
adequately treated for comorbid disorders, such as depression, anxiety, and ADHD. The 
possibility of treatment-emergent mania with antidepressants and stimulants should be 
considered, particularly in patients with a family history of bipolar disorder or subthreshold 
manic symptoms. Psychoeducation for families and patients is critical. These patients should 
be referred to available psychosocial supports, ideally those reviewed above, and carefully 
followed, given the high rates of suicide in emerging bipolar disorder.
Conclusion
Research is rapidly advancing in both the psychosis prodrome and the bipolar disorder 
prodrome, but work remains, particularly on early prospective identification and 
intervention. It is clear that preventative pharmacologic treatments (antipsychotics for 
psychosis prodrome and mood stabilizers for bipolar disorder prodrome) are not supported 
by sufficient evidence; however, specialized psychosocial treatments appear to have a more 
favorable risk-benefit ratio. In the clinic, treatment of psychiatric symptoms that prodromal 
patients already manifest, promotion of positive health behaviors (e.g., regular sleep, 
avoidance of drugs of abuse) and close clinical monitoring, is clearly indicated.
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